RUA Life Sciences plc
RUA.L · LSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -75.00 | 0.04 | 1.83 | -0.39 |
| FCF Yield | -3.75% | -47.09% | -14.21% | -30.04% |
| EV / EBITDA | 12.37 | 0.38 | -5.35 | -4.05 |
| Quality | ||||
| ROIC | -24.31% | -17.86% | -37.12% | -28.70% |
| Gross Margin | 77.12% | 78.32% | 65.76% | 64.31% |
| Cash Conversion Ratio | -219.00 | 0.92 | 0.59 | 1.14 |
| Growth | ||||
| Revenue 3-Year CAGR | 23.59% | 10.47% | 12.56% | 49.23% |
| Free Cash Flow Growth | 79.68% | 14.79% | 50.29% | -59.81% |
| Safety | ||||
| Net Debt / EBITDA | -6.33 | 2.25 | 0.52 | 1.28 |
| Interest Coverage | 0.00 | -23.34 | -144.13 | -294.00 |
| Efficiency | ||||
| Inventory Turnover | 1.25 | 4.24 | 9.21 | 4.68 |
| Cash Conversion Cycle | 124.45 | 67.11 | 117.09 | 213.18 |